BUPRENEX
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUPRENEX is an injectable small-molecule treatment approved in 1981 for post-traumatic stress disorder and alcohol use disorder. The mechanism of action is not specified in available data, but the product represents a legacy therapeutic approach in the behavioral health space. It is manufactured by Indivior as an NDA product.
LOE Approaching
With LOE approaching and minimal current commercial activity, this product faces significant transition challenges requiring strategic restructuring or lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE status, BUPRENEX represents a contracting career opportunity at Indivior. Professionals assigned to this product should anticipate portfolio deprioritization and seek internal mobility to growth-stage assets.
Brand ManagerField Sales Representative
Worked on BUPRENEX at Indivior? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.